The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
SourceBritish Journal of Clinical Pharmacology, 51, 6, (2001), pp. 631--5
Article / Letter to editor
Display more detailsDisplay less details
British Journal of Clinical Pharmacology
SubjectThe role of cytokines in the pathophysiology of febrile illnesses and in host defense against infections; Rational Use of Drugs and Pharmaco-epidemiology; De rol van cytokinen in de pathofysiologie van koortsende ziekten en in de afweer tegen infecties; Rationeel Geneesmiddelengebruik en Farmaco-epidemiologie
AIMS: To study the effect of fluconazole on the steady-state pharmacokinetics of the protease inhibitors ritonavir and saquinavir in HIV-1-infected patients. METHODS: Five subjects treated with saquinavir and three with ritonavir received the protease inhibitor alone (saquinavir 1200 mg three times daily, ritonavir 600 mg twice daily) on day 1, and the same protease inhibitor in combination with fluconazole (400 mg on day 2 and 200 mg on days 3 to 8). Pharmacokinetic parameters were determined on days 1 and 8. RESULTS: In the saquinavir group, the median increase in the area under the plasma concentration vs time curve was 50% from 1800 microg l(-1) h to 2700 microg l(-1) h (P = 0.04, median increase: 900 microg l(-1) h; 2.5 and 97.5 percentile: 500-1300), and 56% for the peak concentration in plasma (from 550 to 870 microg l(-1), P = 0.04; median increase: 320 microg l(-1) h, 2.5 and 97.5 percentile: 60-450 microg l(-1)). In the ritonavir group, there were no detectable changes in the pharmacokinetic parameters on addition of fluconazole. CONCLUSIONS: Because of the favourable safety profile of saquinavir, dose adjustments are probably not necessary with concomitant use of fluconazole, as is the case for ritonavir.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.